ATE527544T1 - Vorhersage von letalität und detektion von schweren erkrankungen - Google Patents

Vorhersage von letalität und detektion von schweren erkrankungen

Info

Publication number
ATE527544T1
ATE527544T1 AT10171764T AT10171764T ATE527544T1 AT E527544 T1 ATE527544 T1 AT E527544T1 AT 10171764 T AT10171764 T AT 10171764T AT 10171764 T AT10171764 T AT 10171764T AT E527544 T1 ATE527544 T1 AT E527544T1
Authority
AT
Austria
Prior art keywords
prediction
detection
lethality
serious diseases
hospital
Prior art date
Application number
AT10171764T
Other languages
English (en)
Inventor
James V Snider
Sven Jacobson
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Application granted granted Critical
Publication of ATE527544T1 publication Critical patent/ATE527544T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
AT10171764T 2006-04-24 2007-04-24 Vorhersage von letalität und detektion von schweren erkrankungen ATE527544T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79435406P 2006-04-24 2006-04-24
US80036206P 2006-05-15 2006-05-15
US90460807P 2007-03-02 2007-03-02

Publications (1)

Publication Number Publication Date
ATE527544T1 true ATE527544T1 (de) 2011-10-15

Family

ID=38656334

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10171764T ATE527544T1 (de) 2006-04-24 2007-04-24 Vorhersage von letalität und detektion von schweren erkrankungen
AT07761219T ATE476657T1 (de) 2006-04-24 2007-04-24 Vorhersage von letalität und detektion von schweren erkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07761219T ATE476657T1 (de) 2006-04-24 2007-04-24 Vorhersage von letalität und detektion von schweren erkrankungen

Country Status (12)

Country Link
US (7) US7998683B2 (de)
EP (5) EP2241888B1 (de)
JP (4) JP5383480B2 (de)
AT (2) ATE527544T1 (de)
AU (1) AU2007244927B2 (de)
CA (1) CA2650201C (de)
DE (1) DE602007008224D1 (de)
DK (3) DK2386860T3 (de)
ES (4) ES2378314T3 (de)
HK (3) HK1164443A1 (de)
PL (2) PL2848938T3 (de)
WO (1) WO2007127749A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
EP1731910A1 (de) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten
JP5383480B2 (ja) 2006-04-24 2014-01-08 クリティカル ケア ダイアグノスティクス インコーポレイテッド 致死性の予測および重大な疾患の検出
ATE517341T1 (de) * 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
EP3059594A1 (de) * 2006-05-01 2016-08-24 Critical Care Diagnostics, Inc. Prognose von herz-kreislauf-erkrankung
PL2019965T3 (pl) * 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
WO2007140231A2 (en) * 2006-05-25 2007-12-06 Momenta Pharmaceutical, Inc. Low molecular weight heparin composition and uses thereof
US11389080B2 (en) 2007-11-28 2022-07-19 Intervet Inc. System and method for diagnosis of bovine diseases using auscultation analysis
WO2009100907A1 (en) * 2008-02-14 2009-08-20 Dianeering Diagnostics Engineering And Research Gmbh Means and methods for assessing the risk of patients presenting to emergency departments based on very low concentrations of troponin i or t or using a combination of markers
WO2009105522A1 (en) * 2008-02-20 2009-08-27 Momenta Pharmaceuticals, Inc. Methods of making low molecular weight heparin compositions
PT2660599E (pt) * 2008-04-18 2014-11-28 Critical Care Diagnostics Inc Predição do risco de eventos cardíacos adversos maiores
EP2141499A1 (de) * 2008-07-02 2010-01-06 Apoptec AG COPD-Diagnose
US9883799B2 (en) * 2008-10-16 2018-02-06 Fresenius Medical Care Holdings, Inc. Method of identifying when a patient undergoing hemodialysis is at increased risk of death
US20100099958A1 (en) * 2008-10-16 2010-04-22 Fresenius Medical Care Holdings Inc. Method of identifying when a patient undergoing hemodialysis is at increased risk of death
US10064580B2 (en) 2008-11-07 2018-09-04 Intervet Inc. System and method for determining antibiotic effectiveness in respiratory diseased animals using auscultation analysis
JP2012063140A (ja) * 2008-12-15 2012-03-29 Hokkaido Univ 糖鎖分析による肺がんの診断方法
JP2012063139A (ja) * 2008-12-15 2012-03-29 Hokkaido Univ 糖鎖分析による膵臓がんの診断方法
EP2480237A1 (de) * 2009-09-23 2012-08-01 Momenta Pharmaceuticals, Inc. Behandlungsverfahren mit einer heparinzusammensetzung von geringem molekulargewicht
CN102812359A (zh) * 2009-11-13 2012-12-05 Bg医药公司 心肌梗死的风险因子和预测
JP6092092B2 (ja) * 2010-03-26 2017-03-08 マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ 腎機能障害、糸球体濾過速度、呼吸困難、急性心不全、左心室肥大、心線維症、子癇前症、妊娠関連蛋白尿のバイオマーカーとしてのｌｔｂｐ２
WO2011127412A2 (en) 2010-04-09 2011-10-13 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
JP2011232164A (ja) * 2010-04-27 2011-11-17 Keio Gijuku 肝臓疾患マーカー、その測定方法、装置及び医薬品の検定方法
US20110295613A1 (en) * 2010-05-28 2011-12-01 Martin Coyne Inpatient utilization management system and method
US20130302841A1 (en) * 2010-11-01 2013-11-14 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10203321B2 (en) 2010-12-02 2019-02-12 Fresenius Medical Care Holdings, Inc. Method of identifying when a patient undergoing hemodialysis is at increased risk of death
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
PL2734222T3 (pl) 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej
US20130157290A1 (en) * 2011-12-16 2013-06-20 Yves Levy Soluble st2 as a marker for disease
ES2709697T3 (es) 2012-05-18 2019-04-17 Critical Care Diagnostics Inc Procedimientos de tratamiento o predicción del riesgo de un evento de taquiarritmia ventricular
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
CN107478841A (zh) * 2012-08-16 2017-12-15 重症监护诊断股份有限公司 预测患高血压风险的方法
SG11201501271TA (en) * 2012-08-21 2015-03-30 Critical Care Diagnostics Inc Multimarker risk stratification
AU2014215675B2 (en) 2013-02-06 2018-08-30 Intervet International B.V. System and method for determining antibiotic effectiveness in respiratory diseased using auscultation analysis
CN106461636A (zh) 2014-01-10 2017-02-22 重症监护诊断股份有限公司 用于测定心力衰竭风险的方法和系统
CA2961340C (en) 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
WO2016066698A1 (en) 2014-10-29 2016-05-06 Roche Diagnostics Gmbh Biomarkers for risk prediction of mortality
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
CR20170240A (es) 2014-11-10 2018-04-03 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
CN106952043B (zh) * 2017-03-23 2021-04-13 国家电网公司客户服务中心 一种计划停电敏感度评估方法和装置
CN108982871B (zh) * 2018-07-19 2021-09-24 北京市心肺血管疾病研究所 血清sST2在小儿扩张型心肌病预后中的应用
WO2021183849A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2023201054A1 (en) * 2022-04-15 2023-10-19 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) * 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
JPH0731479Y2 (ja) 1989-06-02 1995-07-19 内橋エステック株式会社 温度ヒューズ
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JPH0731479A (ja) 1993-02-23 1995-02-03 Shinichi Tominaga マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1998007754A1 (en) 1996-08-23 1998-02-26 Human Genome Sciences, Inc. T1 receptor-like ligand ii
WO1998038311A1 (en) 1997-02-28 1998-09-03 Human Genome Sciences, Inc. T1/st2-receptor ligand iii
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
ES2239801T3 (es) * 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
JP5264026B2 (ja) * 1997-06-10 2013-08-14 エルパス・インコーポレイテッド 心疾患の早期発見のための方法
US6828107B2 (en) 1997-09-11 2004-12-07 Shionogi & Co., Ltd. Immunoassay method for BNP
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
GB9827348D0 (en) 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
EP1140137A2 (de) 1998-12-18 2001-10-10 Scios Inc. Methode zur detektion und verwendung von in krankenheitzuständen differentiell exprimierte gene
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
WO2001013900A2 (en) 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
AU2001218871A1 (en) * 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
BR0107157A (pt) 2000-08-22 2002-07-16 Brigham And Womens Hospital In Diagnose e tratamento de condições cardiovasculares
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
DE60235416D1 (de) 2001-05-04 2010-04-01 Biosite Inc Diagnostische Marker der akuten koronaren Syndrome und ihre Verwendungen
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) * 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
US7670769B2 (en) * 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
AU2003239544A1 (en) * 2002-05-24 2003-12-12 Tularik Inc. Amplification and overexpression of oncogenes
US8263325B2 (en) * 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
WO2004056868A2 (en) 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
US20040133079A1 (en) * 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050123451A1 (en) * 2003-10-31 2005-06-09 Hiroshi Nomura System and apparatus for body fluid analysis using surface-textured optical materials
CA3050151C (en) * 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
US7781219B2 (en) 2003-12-05 2010-08-24 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) * 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
EP1833766A1 (de) 2004-12-17 2007-09-19 Clearwater Systems Corp. Verfahren und vorrichtung zur behandlung von fluiden
PT1849009E (pt) 2005-01-24 2009-01-14 Hoffann La Roche Ag F Utilização de hormonas cardíacas para avaliar um risco cardiovascular em relação à administração de fármacos anti-inflamatórios
EP1731910A1 (de) 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten
US20070021977A1 (en) * 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
JP5383480B2 (ja) 2006-04-24 2014-01-08 クリティカル ケア ダイアグノスティクス インコーポレイテッド 致死性の予測および重大な疾患の検出
ATE517341T1 (de) 2006-04-27 2011-08-15 Critical Care Diagnostics Inc Interleukin-33 (il-33) zur diagnose und vorhersage von herz-gefäss-erkrankungen
EP3059594A1 (de) 2006-05-01 2016-08-24 Critical Care Diagnostics, Inc. Prognose von herz-kreislauf-erkrankung
PL2019965T3 (pl) 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
US8147817B2 (en) * 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
WO2008116083A1 (en) 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CA2705500A1 (en) 2007-05-11 2008-11-20 Tufts Medical Center Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
GB0713404D0 (en) 2007-07-11 2007-08-22 Integra Sp Ipr Ltd Altio graph
WO2009040133A1 (en) 2007-09-26 2009-04-02 Universitätsklinikum Heidelberg Osteopontin as novel prognostic biomarker for heart failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
PT2660599E (pt) 2008-04-18 2014-11-28 Critical Care Diagnostics Inc Predição do risco de eventos cardíacos adversos maiores
WO2010054810A1 (en) 2008-11-11 2010-05-20 B.R.A.H.M.S Ag Prognosis and risk assessment in patients suffering from heart failure by determining the level of adm and bnp
CN102812359A (zh) 2009-11-13 2012-12-05 Bg医药公司 心肌梗死的风险因子和预测
WO2011127412A2 (en) 2010-04-09 2011-10-13 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
US20130302841A1 (en) 2010-11-01 2013-11-14 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
PL2734222T3 (pl) 2011-07-18 2017-03-31 Critical Care Diagnostics, Inc. Sposoby leczenia chorób układu krążenia i prognozowania skuteczności terapii ruchowej
ES2709697T3 (es) 2012-05-18 2019-04-17 Critical Care Diagnostics Inc Procedimientos de tratamiento o predicción del riesgo de un evento de taquiarritmia ventricular
CN107478841A (zh) 2012-08-16 2017-12-15 重症监护诊断股份有限公司 预测患高血压风险的方法
SG11201501271TA (en) 2012-08-21 2015-03-30 Critical Care Diagnostics Inc Multimarker risk stratification
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
CN106461636A (zh) 2014-01-10 2017-02-22 重症监护诊断股份有限公司 用于测定心力衰竭风险的方法和系统
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
HK1164443A1 (en) 2012-09-21
HK1208724A1 (en) 2016-03-11
EP2386860A2 (de) 2011-11-16
PL2848938T3 (pl) 2018-02-28
US20190041403A1 (en) 2019-02-07
AU2007244927B2 (en) 2012-01-12
EP2010912A4 (de) 2009-06-10
EP2241888B1 (de) 2011-10-05
WO2007127749A3 (en) 2008-03-20
US11016103B2 (en) 2021-05-25
EP2241888A3 (de) 2010-11-03
ES2529618T3 (es) 2015-02-23
JP2009534691A (ja) 2009-09-24
PL2386860T4 (pl) 2015-09-30
JP6214604B2 (ja) 2017-10-18
US7998683B2 (en) 2011-08-16
US20210255200A1 (en) 2021-08-19
JP2017215347A (ja) 2017-12-07
US10067146B2 (en) 2018-09-04
EP2386860B1 (de) 2014-11-05
US20120040381A1 (en) 2012-02-16
DK2848938T3 (da) 2017-11-13
WO2007127749A2 (en) 2007-11-08
JP5383480B2 (ja) 2014-01-08
US8617825B2 (en) 2013-12-31
JP2016001193A (ja) 2016-01-07
PL2386860T3 (pl) 2015-08-31
EP2848938B1 (de) 2017-08-02
ATE476657T1 (de) 2010-08-15
DK2386860T3 (en) 2015-02-09
DK2241888T3 (da) 2012-01-30
US9057733B2 (en) 2015-06-16
US20110262941A1 (en) 2011-10-27
EP2848938A1 (de) 2015-03-18
CA2650201A1 (en) 2007-11-08
EP2386860A3 (de) 2012-02-22
US9568481B2 (en) 2017-02-14
JP2012181200A (ja) 2012-09-20
EP3255432A1 (de) 2017-12-13
ES2378314T3 (es) 2012-04-11
HK1248311B (zh) 2020-03-20
US20070248981A1 (en) 2007-10-25
US20140045200A1 (en) 2014-02-13
EP2241888A2 (de) 2010-10-20
DE602007008224D1 (de) 2010-09-16
AU2007244927A1 (en) 2007-11-08
US20170131294A1 (en) 2017-05-11
ES2351623T3 (es) 2011-02-08
ES2646142T3 (es) 2017-12-12
CA2650201C (en) 2020-10-20
EP2010912B1 (de) 2010-08-04
EP2010912A2 (de) 2009-01-07
EP3255432B1 (de) 2019-01-23
JP5806165B2 (ja) 2015-11-10

Similar Documents

Publication Publication Date Title
ATE527544T1 (de) Vorhersage von letalität und detektion von schweren erkrankungen
Vijayan et al. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy
Patel et al. Biomarkers for wound healing and their evaluation
Fan et al. Diagnosing sepsis–The role of laboratory medicine
Selek et al. Evaluation of total oxidative status in adult attention deficit hyperactivity disorder and its diagnostic implications
ATE554386T1 (de) Verbesserte immunoassayverfahren
WO2010057184A3 (en) Methods for detection of acute kidney injury in humans
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
JP2009501333A5 (de)
Wijeratne et al. Cell‐free plasma DNA as a prognostic marker in intensive treatment unit patients
NO20083820L (no) Deteksjon av kreft ved forhoyede nivaer av BCL-2
Novotny et al. Use of procalcitonin for early prediction of lethal outcome of postoperative sepsis
Letendre et al. Measurement of plasma cell‐free DNA concentrations in dogs with sepsis, trauma, and neoplasia
DE602005022709D1 (de) Quantifizierungsverfahren für die vegf isoformen einer biologischen probe
Albert et al. A novel method for a fast diagnosis of septic arthritis using mid infrared and deported spectroscopy
CY1112423T1 (el) Αναλυτικη συσκευη μικροεπεξεργαστη μιας χρησης
Hou et al. Branched DNA-based Alu quantitative assay for cell-free plasma DNA levels in patients with sepsis or systemic inflammatory response syndrome
Yenibertiz et al. The comparison of GNRI and other nutritional indexes on short-term survival in geriatric patients treated for respiratory failure
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
Wang et al. An evaluation of aging measures: from biomarkers to clocks
WO2008035204A3 (en) Prediction and prophylactic treatment of type 1 diabetes
ATE509270T1 (de) Aus blutplättchen gewonnene mikropartikel als neue diagnosemarker für eine herz-kreislauf- erkrankung
de AB Cobra et al. Cell-free deoxyribonucleic acid: a potential biomarker of chronic periprosthetic knee joint infection
Mamone et al. Assessment of a veterinary dipstick for determination of urine protein/creatinine ratio in canines
RU2195667C2 (ru) Способ прогнозирования течения геморрагического инсульта

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2241888

Country of ref document: EP